B
Bull
Bull · 25%CHEK
$0.90
Scenario price
$1.610
+0.031 (+1.90%)At close
Loading chart…
- High
- 1.675
- Open
- 1.570
- VWAP
- 1.59
- Vol
- 58.97K
- Mkt Cap
- 11.46M
- Low
- 1.500
- Amount
- 94.04K
- EV/EBITDA, TTM
- 0.00
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Analyst Ratings (3)
Buy
3 Buy
0 Hold
0 Sell
Current: 1.61
Low
—
Average
—
High
—
HC Wainwright & Co.
Hold
—
2023-06-07
HC Wainwright & Co.
2023-06-07
Price Target
—
Hold
HC Wainwright & Co.
Strong Buy
$7
2023-05-15
HC Wainwright & Co.
2023-05-15
Price Target
$7
Strong Buy
HC Wainwright & Co.
Strong Buy
$7
2023-04-05
HC Wainwright & Co.
2023-04-05
Price Target
$7
Strong Buy
HC Wainwright & Co.
Strong Buy
—
2021-08-09
HC Wainwright & Co.
2021-08-09
Price Target
—
Strong Buy
Dawson James
Hold
—
2021-03-17
Dawson James
2021-03-17
Price Target
—
Hold
Valuation Metrics
The current forward P/E ratio for Check Cap Ltd (CHEK) is 0.00, compared to its 5-year average forward P/E of -2.37.
Alphio AI Price Scenarios for CHEK
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
2.009-16TipRanks3 Penny Stocks to Keep an Eye on This Week, 9/16/25
4.509-15BenzingaCrude Oil Increases by 1%; New York's Manufacturing Activity Declines in September
4.509-15BenzingaNasdaq Rises by More Than 100 Points; Tesla Stock Soars
- 8.509-15TipRanks
M&A Update: Check-Cap (CHEK) Shares Surge Following MBody AI Merger Announcement
4.509-15BenzingaStock Market Update: S&P 500 Futures Increase, Nasdaq Declines in Varied Trading—Focus on Nvidia, Hain Celestial, and Check Cap
CHEK FAQ — answered by Alphio AI
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon. It operates in the Healthcare sector (X- RAY APPARATUS AND TUBES AND RELATED IRRADIATION industry).
3 analysts cover CHEK: 3 rate it Buy, 0 Hold and 0 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.